Results 121 to 130 of about 30,003 (287)
Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy [PDF]
, 2017 Biosynthetic human insulin and insulin analogues are the mainstay of insulin therapy for both type 1 and type 2 diabetes although access to human insulin at affordable prices remains a global issue.
Landgraf, Wolfgang +3 more
core +1 more source
The protein science of biosimilars [PDF]
, 2006 Martin K. Kuhlmann, Adrian Covic
openalex +1 more source
Clinical &Experimental Allergy, EarlyView.Chronic spontaneous urticaria (CSU) is a debilitating skin disorder with significant impact upon quality of life. Current guidelines advocate stepwise treatment of standard dose antihistamines, high dose antihistamines, omalizumab and ciclosporin.
Katie Ridge +7 more
wiley +1 more source
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Drug Design, Development and Therapy, 2017 Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Borrás Pérez MV +5 more
doaj
Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists [PDF]
, 2015 Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs.
Baji, Petra +7 more
core
BiologicsUstekinumab is a fully human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 subunit of interleukins (IL-) 12 and 23, inhibiting their activity by preventing binding to their receptors. The European extension of the patent (Supplementary Protection Certificate) of ustekinumab expired on July 20, 2024.
Elena Carmona-Rocha, Lluís Puig
openaire +2 more sources
The Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to GH
Clinical Endocrinology, EarlyView.ABSTRACT Introduction Recombinant human growth hormone (GH) therapy shows variable growth responses in patients with growth hormone deficiency (GHD), highlighting the need for reliable biomarkers to predict individual sensitivity. Objective This study investigated circulating microRNAs (miRNAs) involved in growth plate regulation during GH therapy in ...
Caroline Rosa Pellicciari +8 more
wiley +1 more source
A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]
, 2015 In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H. +16 more
core
Non‐Clinical Safety Studies on Biosimilar Recombinant Human Erythropoietin [PDF]
, 2007 Michael J. Parnham +2 more
openalex +1 more source